Reimbursed Care Access in Philippines

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Philippine Drug Enforcement Agency (PDEA) has issued public advisories warning against use, sale, distribution and cultivation of ‘magic mushrooms’ containing psilocybin. # Republic Act No. 9165 incorporates the UN psychotropic schedules into national law and provides the statutory framework used to prohibit and control psychotropic substances. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Multiple recent law‑enforcement seizures and public statements show MDMA (ecstasy) is treated as a prohibited dangerous drug under RA 9165; seizures are routinely processed through PDEA and Customs under RA 9165 enforcement provisions. Example seizure reports: Bureau of Customs / PDEA public notices confirming MDMA as a dangerous drug under RA 9165. #. #.

Ketamine’s S‑enantiomer (esketamine; marketed as Spravato in some jurisdictions) is not documented as a nationally registered, reimbursed product in publicly available Philippine regulatory or reimbursement sources at the time of this report; there is no public record of a national marketing authorization or PhilHealth coverage for esketamine in the Philippines. Esketamine-like products derived from ketamine would be subject to national drug control frameworks and require registration through the Philippines’ regulatory authority for medicines before routine clinical or reimbursed use. For the controlling legal framework and the DDB regulatory approach to ketamine generally see DDB Board Regulation No. 3 (inclusion of ketamine as a dangerous drug with a medical-use exception). # #.

Ketamine (any material, compound, mixture or preparation which contains any quantity of KETAMINE, including salts/isomers) is formally included in the Philippines’ list of dangerous drugs but expressly excepted from criminal sanction when prescribed by a licensed practitioner—i.e., it is a controlled medicine with an explicit medical‑use carve‑out. The Dangerous Drugs Board promulgated DDB Board Regulation No. 3 (July 19, 2005) classifying ketamine as a dangerous drug while providing the exception for preparations prescribed by licensed practitioners. #. Republic Act No. 9165 provides the statutory basis for schedules and control measures and incorporates international psychotropic scheduling into national law. #.

Medical access and reimbursement context: in the Philippines ketamine is routinely available and used within hospitals and clinics for approved medical indications (primarily anesthesia, analgesia, emergency medicine) and, in some private clinical practices, for off‑label psychiatric use (e.g., intravenous ketamine for refractory depression) under physician supervision. Ketamine appears on Philippine hospital pharmaceutical lists and procurement/pricing schedules (examples include institutional formularies that list ketamine injection), indicating routine procurement for clinical use in both public and private hospitals; such use is generally reimbursed indirectly as part of the hospital/service package or procedure (i.e., ketamine as an anesthetic/medication is covered within PhilHealth’s case rates or hospital billing structures rather than as a separately reimbursed psychedelic psychotherapy product). Example hospital formulary listing shows ketamine injection in institutional drug lists. # # #.

Important clinical / reimbursement nuance: there is no established, nationally reimbursed model in the Philippines for ketamine‑assisted psychotherapy as a licensed psychiatric treatment pathway comparable to approved indications in other jurisdictions; when ketamine is used off‑label for psychiatric indications it is typically paid for by patients (private pay) or billed to hospitals under non‑specific case rates—coverage depends on the PhilHealth benefit package, membership class, and whether the service is delivered in an accredited facility. PhilHealth reimbursement tends to cover recognized medical procedures and inpatient/ambulatory case rates rather than specialized psychedelic therapy pathways unless a specific product or service is formally included in the benefits schedule. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT is controlled under the national implementation of international psychotropic schedules embedded in RA 9165; there is no publicly available regulatory pathway authorizing routine medical or reimbursed use. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT falls within the broader class of controlled tryptamines and is treated as a prohibited substance in enforcement and public‑health advisories in the Philippines. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no recognized clinical or reimbursed pathway for ibogaine in the Philippines; possession/use outside approved research may trigger criminal enforcement under RA 9165. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Plant preparations containing DMT or other scheduled psychotropic constituents (such as ayahuasca brews) are controlled under the national implementation of international schedules; traditional or sacramental claims do not create an authorized medical use absent specific legal exemption. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti fall under the scope of the psychotropic control framework in RA 9165 as implemented by the Dangerous Drugs Board and PDEA; there is no public regulatory pathway for medical or reimbursed mescaline therapy. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The text of RA 9165 and implementing reproductions reference UN psychotropic listings and specifically call out certain 2C‑series compounds (for example 2C‑B is referenced in the law’s reproduction of UN lists), placing 2C analogues within the national control regime; enforcement actions and seizures reflect a prohibitionist approach. # #.